BUS3022 Social Responsibility in Practice Assignment Example 2026 | University of Northampton

Introduction

The pharmaceutical industry worldwide exists at the crossroads of creativity, human health and business; thus, ethical practices, sustainability, and social responsibility are the key factors to ultimate corporate validity (Das, 2025). In this report, as a CSR and sustainability consultant contracted by GlaxoSmithKline (GSK), it has assessed ethical, legal, and social responsibility issues that are inherent in the international pharmaceutical industry and their effects on the company. The report begins by giving a brief background of the industry in terms of its structure, major actors, production sites and nature of its supply chain. Then, it focuses on the key points of the pharmaceutical value chain to determine the real and potential risks to ethical, sustainability, and social responsibility, which occur during global activities. Continuing on this analysis of this industry at the level, the report presents a critical analysis of the particular issues that GSK faces in the context of an international environment and draws a close by giving some practical and knowledge-based suggestions as to how to alleviate these risks.

Pharmaceutical Industry Overview and Structure

The pharmaceutical market in the world is a very research-intensive and highly regulated field that is dominated by a few large multinational corporations (Khakurel, et al., 2019). The market faces an oligopoly structure where major players like GlaxoSmithKline, Pfizer, Novartis, and Roche are involved in the industry, with barriers to entry being high, capital investment being significant, and owing to high levels of intellectual property protection. Innovation, therapeutic specialisation, and global market access are the main drivers of competition as opposed to price. The industry provides a wide range of customers, such as the public health care system, individual providers, insurance companies, and individual consumers, with demand being determined by demographic transformation, prevalence of diseases, as well as government health policies (Liu, et al., 2025). The largest pharmaceutical markets are based in North America and Europe, whereas the emerging economies are the major growth prospects, given the increased access to healthcare and population increase.

The production of pharmaceuticals is structured in a value chain that is globally scattered. The primary concentration of research and development activities is in the United States, the United Kingdom, and the European Union, and manufacturing activities are becoming more and more distributed in India, China, and other cost-effective regions (Vivek Wadhwa, 2008). Among the most critical early phases of the supply chain is the sourcing of Active Pharmaceutical Ingredients (APIs), where a significant portion of the API manufacturing is carried out by India and China. The dependence on geographically-focused suppliers has made the industry susceptible to supply risks and logistical risks. The product offerings of the industry are prescription medicines, vaccines, and consumer healthcare products sold both locally and internationally, which is an indication of the globalization of pharmaceutical production, distribution, and consumption (Peña, et al., 2021).

Value Chain, Key Ethical, Sustainability, and Social Responsibility Issues

The pharmaceutical value chain is highly disaggregated on a global level. It involves various, mutually supporting steps, and the first one is the sourcing of the raw material and Active Pharmaceutical Ingredients (APIs), followed by the manufacturing, quality control, distribution, and ultimately market access and consumption (Fadojutim, 2024). The production of APIs is significantly located in India and China, which dominate the global supply so cost efficiency and chemical production capability generate structural dependencies in the industry (Pathan, 2025). The manufacturing and formulation processes are in both developed and emerging economies, and strict compliance with the quality and regulatory requirements is applicable. Manufactured products are marketed to the healthcare systems, pharmacies, and consumers across the world through a complicated logistics system, and ultimate access depends on the pricing regimes of countries, patent protection, and national health infrastructure. This value chain that is internationally distributed puts pharmaceutical companies at risk of a wide range of ethical, legal, and socio-cultural issues, which differ significantly between jurisdictions (Dubois, 2025).

Ethical and sustainability issues in the upstream stage are associated with the fact that chemical-intensive API production has an adverse effect on the environment, such as water contamination and hazardous waste disposal, which is usually in areas with uneven regulation and enforcement (Caldeira, et al., 2024). The other current social responsibility risks are labor and worker safety in the supplier premises, which is worsened by the lack of transparency in the supply chain. Ethical concerns in the context of clinical trials are also especially relevant during production and R&D processes, where in the low- and middle-income countries (LMICs), socio-economic vulnerabilities can compromise the fully informed consent. Pfizer Trovan clinical trial in Nigeria that received international attention due to the alleged ethical violations concerning consent and regulatory permission, and demonstrates the reputational and legal risks of research governance failures (Erinosho, 2008). Other issues that need to be mentioned are animal testing and the carbon footprint of the manufacturing processes that are energy-intensive. Ethical dilemmas on drug pricing and patent protection at the distribution and market access level are deeply rooted and create a conflict between the intellectual property rights and the right to health, most particularly in times of health emergencies. The COVID-19 vaccine patent controversy in the world brought to the limelight the nature of legal frameworks in limiting equitable access in LMICs. Lastly, the marketing and governance practices can be associated with the risks of unethical promotion, non-compliance with regulations in different jurisdictions, and corruption, in particular, when the system of oversight is poorly established (Lupu & Tiganasu , 2023).

GlaxoSmithKline (GSK): Ethical, Sustainability, and SR Challenges

GlaxoSmithKline (GSK) is a part of a global complex pharmaceutical ecosystem, in which the ethical and sustainability-related issues are closely interconnected with the business strategy (Zec, 2024). Supply chain responsibility and environmental impact are two of the most material issues of the company. GSK purchases much of the Active Pharmaceutical Ingredients (APIs) in India and China, where the enforcement of regulations is inconsistent and environmental standards do not align with the EU ones. GSK was sourced to these countries around 65% in 2024, both in terms of cost-effectiveness and exposure to upstream sustainability risks (Schondelmeyer, 2023). Ecological issues are chemical effluents, hazardous waste, and water consumption, whereas social risks are the safety of workers, labor rights, and inadequate transparency throughout the networks of suppliers. Despite GSK having a Supplier Code of Conduct and conducting regular audits, it still has a policy and practice disjuncture in that audits do not always provide a comprehensive view of the local labor conditions or environmental compliance (GSK, 2021). The problem is made worse by the fact that the pharmaceutical supply chain is quite complex and multi-layered, and proactive management of it is needed to prevent unethical and unsustainable operations.

The second critical area is the issue of medicines and pricing ethics that has a direct impact on the social legitimacy of GSK and health-related contributions worldwide (Medicine, 2024 ). The conflict between the shareholder returns and fair access to healthcare is evident in the work of GSK in the low- and middle-income countries. The company has been questioned regarding the cost of vaccines and other critical medicines where cost-recovery efforts may interfere with the access to such products by disadvantaged groups of people (Kheder & Ali, 2014). GlaxoSmithKline meningitis vaccine programme in sub-Saharan Africa stands out as the initial example where access was restricted by pricing and distribution, which was later opened to the communities with lower income (WHO, 2014). In turn, GSK rolled out tiered pricing and donation programs, proving how tricky the process of balancing corporate profit objectives with ethical requirements is. It demonstrates that although policies are in place to improve access, institutional issues, including regulatory requirements, logistical difficulties, and intellectual property structures, still affect the results and need to be managed through a strategic approach.

Lastly, clinical trials, research ethics and governance are still at the center of the international responsibilities of GSK. Trial in different socio-cultural areas presents ethical issues pertaining to informed consent, protection of participants and cultural sensitivity (Marshall, 2023). The imbalance of power between international sponsors and local communities increases the reputational and legal risks, as it has been shown in the past, as the industry as a whole was scrutinized due to how trials are conducted in developing nations. Moreover, another critical governance issue is transparency and trust: investors, regulators, and the population are becoming increasingly insistent on effective ESG reporting and adherence to the international standards, like ICH-GCP (International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice). Overall, this shows that GSK has been generally relatively high on compliance, still, widespread perception and stakeholder trust have had weaknesses, especially when the company’s clinical trial results, pricing, or environmental policies seem to be inconsistent with the professed corporate values (GSK, 2024). The combined effect is that the company has minimal weaknesses in ethical, legal, and socio-cultural responsibilities, which must be critically monitored and actively pursued through the CSR strategy.

Recommendations: Mitigating Ethical, Sustainability and SR Risks at GSK

Enhance Supplier Auditing and Traceability

• Problem Tackled: Problems with the upstream environmental and labor API supply chains.
• Recommended Intervention: Conduct audits of suppliers more often and more frequently, have traceability of multi-tier suppliers, which can be saved on blockchain, and focus on suppliers that exhibit strong ESG performance.
• Ethical Rationale: Helps to improve accountability, minimize the chances of labor abuse and environmental non-compliance, and is consistent with the international CSR principles like the UN Global Compact.
• Impact and limitations Anticipated: The transparency will be improved, and risks will be mitigated, but its implementation will involve a considerable amount of financial resources and cooperation with suppliers that might not be eager to comply with new reporting standards.

Implement Differential Pricing and Access Programs

• Problem Tackled: Inability to afford medicines in the low and middle-income countries.
• Recommended Intervention: Adopt tiered pricing schemes of essential medicines, augmented with specific donation schemes or subsidy schemes in needy areas.
• Ethical Rationale: Level the shareholder returns and equitable access to them in favor of the global health population and the moral imperative of beneficence.
• Impact and limitations Anticipated: More access and availability; there will be financial trade-offs in short-term profit margins that need to be carefully predicted and communicated to investors.

Improve Clinical Trial Transparency

• Problem Tackled: Ethical issues in international research and participant protection.
• Recommended Intervention: Publication of detailed trial protocols and outcomes in publicly available databases, strong consent processes and use of local ethics committees in trial management.
• Ethical Rationale: Advances trust, adheres to ICH-GCP principles, and eliminates reputational and legal risks of trials in LMICs.
• Impact and limitations Anticipated: Compelled stakeholders to have greater confidence and lower risk of litigation; can prolong trial proceedings and raise administrative expenses.

Establish and oversee Carbon Reduction Targets

• Problem Tackled: Green manufacture and distribution.
• Recommended Intervention: Introduce science-based carbon reduction targets based on the Science Based Targets initiative (SBTi), introduce energy-efficient production processes and transition to renewable energy sources.
• Ethical Rationale: Cuts down on the environmental pollution and complies with the international framework of sustainability, like the Paris Agreement.
• Impact and limitations Anticipated: Cost-saving in the long term and environmental sustainability reputation; first-time capital investments can be high, and the project would have to be introduced gradually.

All these recommendations bring about equilibrium of ethical responsibility, legal compliance and business sustainability. Although implementation involves financial investment, coordination, as well as short-term profit trade-offs, they are critical towards countering the reputational, regulatory, and operative risks. The suggested actions reflect the effect of an informed decision-making process, understanding the existence of complexity and conflicting priorities, and the provision of practical, viable solutions that would support the long-term strategic stability of GSK.

Conclusion

The GSK is a firm that functions in an intricate international pharmaceutical setting with the ethical, sustainability, and social responsibility issues that are connected to the commercial needs. The most critical risks are vulnerabilities of the supply chain, some of which are the availability of medicines, the morals of clinical trials, and effects on the environment, each of which has reputational, legal, and operational implications. The recommendations listed have improved supplier audits, differentiated pricing, open clinical trials, and carbon reduction goals, which offer practical measures to reduce these risks without excessive focus on ethical and commercial interests. These measures will enable GSK to reinforce its international leadership, keep its regulatory standards, increase its stakeholder trust, and be long-term sustainable according to the international ethical standards.

Reference list

• Caldeira, C. et al., 2024. Safe and sustainable chemicals and materials: a review of sustainability assessment frameworks. Green Chemistry.
• Das, T., 2025. The Intersection of Corporate Social Responsibility, Sustainability and Community Engagement in Pharmaceutical Industry- A Review.
• Dubois, P., 2025. “Pharmaceutical Regulation and Incentives for Innovation in.
• Erinosho, O., 2008. Ethics for Public Health Research in Africa. Social Science Academy of Nigeria .
• Fadojutim, B., 2024. Exploring the critical factors in pharmaceutical supply chains revealed during COVID-19 and addressing missing links. World Journal of Advanced Research and Reviews.
• GSK, 2021. s.l.: s.n.
• GSK, 2024. Annual Report 2024 GSK Pakistan, s.l.: s.n.
• Khakurel, B., Shrestha , R., Joshi, S. & Thomas, D., 2019. Clinical Pharmacy Education, Practice and Research. s.l.:s.n.
• Kheder , S. I. & Ali, H. M., 2014. Evaluating medicines prices, availability, affordability and price components in Sudan. Sudan Medical Monitor.
• Liu, H., Jiang, J., Yu, L. & Liu, X., 2025. The impact of hospital competition on healthcare quality: evidence from China’s healthcare reform. Frontiers in Public Health.
• Lupu, D. & Tiganasu , R., 2023. COVID-19 vaccination and governance in the case of low, middle and high-income countries. BMC Public Health.
• Marshall, P. A., 2023. Ethical challenges in study design and informed consent for health research in resource-poor settings. s.l.:s.n.
• Medicine, A. t., 2024 . Access to Medicine.
• Pathan, F. A., 2025. India’s Import Landscape: Strategic Analysis,Regulatory Framework, and Policy Implications. Journal Of Advance and Future Reaserch.
• Peña, . O. G., López Zavala, Á. M. & Ruelas, H. C., 2021. Pharmaceuticals Market, Consumption Trends and Disease Incidence Are Not Driving the Pharmaceutical Research on Water and Wastewater. International Journal of Environmental Research and Public Health.
• Schondelmeyer, S. W., 2023. Designing A Resilient U.S. Drug Supply: Efficient. s.l., s.n.
• Vivek Wadhwa, B. A. R. G. G. J. T. P. E., 2008. The Globalization of Innovation: Pharmaceuticals: Can India and China Cure the Global Pharmaceutical Market.
• WHO, 2014. Meningitis outbreak response in sub-Saharan Africa: WHO guideline, s.l.: WHO.
• Zec, D., 2024. Dataset for ‘Sustainability in the context of the UK pharmaceutical industry (2000-2020): Media representations and stakeholder perceptions.